In the News

Dec 22, 2022

Levine Media Group

Targeting a Novel Checkpoint to Treat Cancer and Autoimmune Conditions

Nov 22, 2022

OncLive

Investigators Look to Translate Positive Results of Eftilagimod Alpha Combination to NSCLC

Nov 21, 2022

In Vivo

The Journey Has Just Begun For LAG-3 Therapeutics

Nov 15, 2022

BioWorld

Immutep’s LAG-3 efti, with pembrolizumab, meets primary endpoint in first-line NSCLC

Nov 03, 2022

SITC

SITC to Hold Press Briefing on Nine Abstracts to be Presented at 37th Annual Meeting

Media

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 30 July 2024 – CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 12 July 2024 – Global Webcast Presentation to discuss companies new clinical data for TACTI-003 Positive Data in Patients with Negative PD-L1 Expression (Cohort B)

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 27 June 2024 – Executive Director and CEO Marc Voigt, Chief Scientific Officer Professor Frédéric Triebel, Chief Medical Officer Dr Florian Vogl, and Senior Vice President Strategic Development Christian Mueller present on Immutep's latest clinical results

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 25 March 2024 – CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.

Efti: A Soluble LAG-3 Protein & MHC Class II Agonist that Unlocks a Broad Anticancer Immune Response

Immutep Limited (ASX:IMM, NASDAQ:IMMP), 31 October 2023 – CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.